Wang CQ, Lim PY, Tan AH. Gamma/delta T cells as cellular vehicles for anti-tumor immunity. Front Immunol. 2023;14:1282758.
Google Scholar
Garber K. gammadelta T cells bring unconventional cancer-targeting to the clinic – again. Nat Biotechnol. 2020;38:389–91.
Google Scholar
Raverdeau M, Cunningham SP, Harmon C, Lynch L. gammadelta T cells in cancer: a small population of lymphocytes with big implications. Clin Transl Immunol. 2019;8:e01080.
Google Scholar
Yazdanifar M, Barbarito G, Bertaina A, Airoldi I. gammadelta T cells: The ideal tool for cancer immunotherapy. Cells. 2020;9:1305.
Google Scholar
Park JH, Lee HK. Function of gammadelta T cells in tumor immunology and their application to cancer therapy. Exp Mol Med. 2021;53:318–27.
Google Scholar
Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science. 1998;279:1737–40.
Google Scholar
Holmen Olofsson G, Idorn M, Carnaz Simoes AM, Aehnlich P, Skadborg SK, Noessner E, et al. Vgamma9Vdelta2 T cells concurrently kill cancer cells and cross-present tumor antigens. Front Immunol. 2021;12:645131.
Google Scholar
Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science. 2005;309:264–8.
Google Scholar
Vasic D, Lee JB, Leung Y, Khatri I, Na Y, Abate-Daga D, et al. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. Sci Immunol. 2022;7:eabl3642.
Google Scholar
Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J, et al. Allogeneic Vgamma9Vdelta2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021;18:427–39.
Google Scholar
Nussbaumer O, Koslowski M. The emerging role of γδ T cells in cancer immunotherapy. Immuno-Oncol Technol. 2019;1:3–10.
Google Scholar
Johnson MD, Witherden DA, Havran WL. The role of tissue-resident T cells in stress surveillance and tissue maintenance. Cells. 2020;9:686.
Google Scholar
Vrieling M, Santema W, Van Rhijn I, Rutten V, Koets A. gammadelta T-cell homing to skin and migration to skin-draining lymph nodes is CCR7 independent. J Immunol. 2012;188:578–84.
Google Scholar
Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, et al. Clinical evaluation of autologous gamma delta T-cell-based immunotherapy for metastatic solid tumors. Br J Cancer. 2011;105:778–86.
Google Scholar
Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2008;57:1599–609.
Google Scholar
Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother. 2007;56:469–76.
Google Scholar
Bustos X, Snedal S, Tordesillas L, Pelle E, Abate-Daga D. Gammadelta T-cell-based adoptive cell therapies against solid epithelial tumors. Cancer J. 2022;28:270–7.
Google Scholar
Makkouk A, Yang XC, Barca T, Lucas A, Turkoz M, Wong JTS, et al. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J Immunother cancer. 2021;9:e003441.
Google Scholar
Lee D, Dunn ZS, Guo W, Rosenthal CJ, Penn NE, Yu Y, et al. Unlocking the potential of allogeneic Vdelta2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering. Nat Commun. 2023;14:6942.
Google Scholar
Zhao Y, Li Y, Wang S, Han J, Lu M, Xu Y, et al. CAR-gammadelta T cells targeting Claudin18.2 show superior cytotoxicity against solid tumor compared to traditional CAR-alphabeta T cells. Cancers. 2025;17:998.
Google Scholar
Frieling JS, Tordesillas L, Bustos XE, Ramello MC, Bishop RT, Cianne JE, et al. gammadelta-Enriched CAR-T-cell therapy for bone metastatic castrate-resistant prostate cancer. Sci Adv. 2023;9:eadf0108.
Google Scholar
Fowler D, Barisa M, Southern A, Nattress C, Hawkins E, Vassalou E, et al. Payload-delivering engineered gammadelta T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma. Sci Transl Med. 2024;16:eadg9814.
Google Scholar
Mazinani M, Rahbarizadeh F. New cell sources for CAR-based immunotherapy. Biomark Res. 2023;11:49.
Google Scholar
Selli ME, Landmann JH, Terekhova M, Lattin J, Heard A, Hsu YS, et al. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction. Blood. 2023;141:3153–65.
Google Scholar
Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N. Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold. Cells. 2020;9:1182.
Google Scholar
Davey AS, Call ME, Call MJ. The influence of chimeric antigen receptor structural domains on clinical outcomes and associated toxicities. Cancers. 2020;13:38.
Google Scholar
Fisher J, Sharma R, Don DW, Barisa M, Hurtado MO, Abramowski P, et al. Engineering γδ T cells limits tonic signaling associated with chimeric antigen receptors. Sci Signal. 2019;12:eaax1872.
Google Scholar
Peng JJ, Wang L, Li Z, Ku CL, Ho PC. Metabolic challenges and interventions in CAR T-cell therapy. Sci Immunol. 2023;8:eabq3016.
Google Scholar
Tan GH, Wong CC. Role of metabolism in adoptive T-cell therapy: strategies and challenges. Antioxid Redox Signal. 2022;37:1303–24.
Google Scholar
O’Sullivan D, Pearce EL. Targeting T-cell metabolism for therapy. Trends Immunol. 2015;36:71–80.
Google Scholar
Huang Y, Shao M, Teng X, Si X, Wu L, Jiang P, et al. Inhibition of CD38 enzymatic activity enhances CAR-T-cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep Med. 2024;5:101400.
Google Scholar
Shi Y, Kotchetkov IS, Dobrin A, Hanina SA, Rajasekhar VK, Healey JH, et al. GLUT1 overexpression enhances CAR T-cell metabolic fitness and anti-tumor efficacy. Mol Ther J Am Soc Gene Ther. 2024;32:2393–405.
Google Scholar
Guerrero JA, Klysz DD, Chen Y, Malipatlolla M, Lone J, Fowler C, et al. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency. Nat Commun. 2024;15:8658.
Google Scholar
Ribeiro ST, Ribot JC, Silva-Santos B. Five layers of receptor signaling in gammadelta T-cell differentiation and activation. Front Immunol. 2015;6:15.
Google Scholar
Nedellec S, Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: from signals to functions. Semin Immunol. 2010;22:199–206.
Google Scholar
Garcillan B, Marin AV, Jimenez-Reinoso A, Briones AC, Munoz-Ruiz M, Garcia-Leon MJ, et al. Gammadelta T lymphocytes in the diagnosis of human T-cell receptor immunodeficiencies. Front Immunol. 2015;6:20.
Google Scholar
Kalyan S, Kabelitz D. Defining the nature of human gammadelta T cells: a biographical sketch of the highly empathetic. Cell Mol Immunol. 2013;10:21–9.
Google Scholar
Fu Y, Maianu L, Melbert BR, Garvey WT. Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation. Blood Cells Mol Dis. 2004;32:182–90.
Google Scholar
Kavanagh Williamson M, Coombes N, Juszczak F, Athanasopoulos M, Khan MB, Eykyn TR, et al. Upregulation of glucose uptake and hexokinase activity of primary human CD4+ T cells in response to infection with HIV-1. Viruses. 2018;10:114.
Google Scholar
Maratou E, Dimitriadis G, Kollias A, Boutati E, Lambadiari V, Mitrou P, et al. Glucose transporter expression on the plasma membrane of resting and activated white blood cells. Eur J Clin Invest. 2007;37:282–90.
Google Scholar
Aehnlich P, Santiago MV, Dam SH, Salo SF, Rahbech A, Olsen LR, et al. Glycolysis inhibition affects proliferation and cytotoxicity of Vgamma9Vdelta2 T cells expanded for adoptive cell therapy. Cytotherapy. 2024;26:1033–45.
Google Scholar
Cao J, Liao S, Zeng F, Liao Q, Luo G, Zhou Y. Effects of altered glycolysis levels on CD8(+) T-cell activation and function. Cell Death Dis. 2023;14:407.
Google Scholar
Menk AV, Scharping NE, Moreci RS, Zeng X, Guy C, Salvatore S, et al. Early TCR signaling induces rapid aerobic glycolysis enabling distinct acute T-cell effector functions. Cell Rep. 2018;22:1509–21.
Google Scholar
O’Sullivan D. The metabolic spectrum of memory T cells. Immunol Cell Biol. 2019;97:636–46.
Google Scholar
van der Windt GJ, Pearce EL. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev. 2012;249:27–42.
Google Scholar
Yoshihara E. TXNIP/TBP-2: a master regulator for glucose homeostasis. Antioxidants. 2020;9:765.
Google Scholar
Kelleher ZT, Wang C, Forrester MT, Foster MW, Marshall HE. ERK-dependent proteasome degradation of TXNIP regulates thioredoxin oxidoreductase activity. J Biol Chem. 2019;294:13336–43.
Google Scholar
Dubuisson A, Mangelinck A, Knockaert S, Zichi A, Becht E, Philippon W, et al. Glucose deprivation and identification of TXNIP as an immunometabolic modulator of T-cell activation in cancer. Front Immunol. 2025;16:1548509.
Google Scholar
Kim S, Ge J, Kim D, Lee JJ, Choi YJ, Chen W, et al. TXNIP-mediated crosstalk between oxidative stress and glucose metabolism. PLoS ONE. 2024;19:e0292655.
Google Scholar
Thielen LA, Chen J, Jing G, Moukha-Chafiq O, Xu G, Jo S, et al. Identification of an anti-diabetic, orally available small molecule that regulates TXNIP expression and glucagon action. Cell Metab. 2020;32:353–65 e8.
Google Scholar
Chu PC, Wu J, Liao XC, Pardo J, Zhao H, Li C, et al. A novel role for p21-activated protein kinase 2 in T-cell activation. J Immunol. 2004;172:7324–34.
Google Scholar
Zhang P, Zhao Y, Zhu X, Sedwick D, Zhang X, Wang Z. Cross-talk between phospho-STAT3 and PLCgamma1 plays a critical role in colorectal tumorigenesis. Mol Cancer Res. 2011;9:1418–28.
Google Scholar
Gomez del Arco P, Martinez-Martinez S, Maldonado JL, Ortega-Perez I, Redondo JM. A role for the p38 MAP kinase pathway in the nuclear shuttling of NFATp. J Biol Chem. 2000;275:13872–8.
Google Scholar
Wu CC, Hsu SC, Shih HM, Lai MZ. Nuclear factor of activated T cells c is a target of p38 mitogen-activated protein kinase in T cells. Mol Cell Biol. 2003;23:6442–54.
Google Scholar
Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293–300.
Google Scholar
Zuo S, Li C, Sun X, Deng B, Zhang Y, Han Y, et al. C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial. Nat Commun. 2024;15:6155.
Google Scholar
von Moos R, Haynes I. Where do bone-targeted agents RANK in breast cancer treatment? J Clin Med. 2013;2:89–102.
Google Scholar
Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med. 2003;198:391–7.
Google Scholar
Pang DJ, Neves JF, Sumaria N, Pennington DJ. Understanding the complexity of gammadelta T-cell subsets in mouse and human. Immunology. 2012;136:283–90.
Google Scholar
Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T-cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17:105.
Google Scholar
Iwasaki M, Tanaka Y, Kobayashi H, Murata-Hirai K, Miyabe H, Sugie T, et al. Expression and function of PD-1 in human gammadelta T cells that recognize phosphoantigens. Eur J Immunol. 2011;41:345–55.
Google Scholar
Nada MH, Wang H, Hussein AJ, Tanaka Y, Morita CT. PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vgamma2Vdelta2 T cells against human prostate cancer. Oncoimmunology. 2021;10:1989789.
Google Scholar
Hoeres T, Holzmann E, Smetak M, Birkmann J, Wilhelm M. PD-1 signaling modulates interferon- γ production by Gamma Delta (γδ) T Cells in response to leukemia. Oncoimmunology. 2019;8:1550618.
Google Scholar
Testi R, Lanier LL. Functional expression of CD28 on T-cell antigen receptor gamma/delta-bearing T lymphocytes. Eur J Immunol. 1989;19:185–8.
Google Scholar
McGraw JM, Witherden DA. gammadelta T-cell costimulatory ligands in antitumor immunity. Explor Immunol. 2022;2:79–97.
Google Scholar
DeBarros A, Chaves-Ferreira M, d’Orey F, Ribot JC, Silva-Santos B. CD70-CD27 interactions provide survival and proliferative signals that regulate T-cell receptor-driven activation of human gammadelta peripheral blood lymphocytes. Eur J Immunol. 2011;41:195–201.
Google Scholar
Bartman CR, Weilandt DR, Shen Y, Lee WD, Han Y, TeSlaa T, et al. Slow TCA flux and ATP production in primary solid tumors but not metastases. Nature. 2023;614:349–57.
Google Scholar
Ishihara M, Miwa H, Fujiwara H, Akahori Y, Kato T, Tanaka Y, et al. alphabeta-T-cell receptor transduction gives superior mitochondrial function to gammadelta-T cells with promising persistence. iScience. 2023;26:107802.
Google Scholar
Muri J, Kopf M. The thioredoxin system: Balancing redox responses in immune cells and tumors. Eur J Immunol. 2023;53:e2249948.
Google Scholar
Tanaka T, Hosoi F, Yamaguchi-Iwai Y, Nakamura H, Masutani H, Ueda S, et al. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J. 2002;21:1695–703.
Google Scholar
Saxena G, Chen J, Shalev A. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. J Biol Chem. 2010;285:3997–4005.
Google Scholar
Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-apoptosis. Diabetes. 2008;57:938–44.
Google Scholar
Kirchmair A, Nemati N, Lamberti G, Trefny M, Krogsdam A, Siller A, et al. 13C tracer analysis reveals the landscape of metabolic checkpoints in human CD8(+) T-cell differentiation and exhaustion. Front Immunol. 2023;14:1267816.
Google Scholar
Muri J, Thut H, Kopf M. The thioredoxin-1 inhibitor Txnip restrains effector T-cell and germinal center B-cell expansion. Eur J Immunol. 2021;51:115–24.
Google Scholar
Xu N, Zhu Y, Han Y, Liu Q, Tong L, Li Y, et al. Targeting MondoA-TXNIP restores antitumour immunity in lactic-acid-induced immunosuppressive microenvironment. Nat Metab. 2025;7:1889–904.
Google Scholar
Klein Geltink RI, O’Sullivan D, Corrado M, Bremser A, Buck MD, Buescher JM, et al. Mitochondrial priming by CD28. Cell. 2017;171:385–97 e11.
Google Scholar
Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell. 2013;49:1167–75.
Google Scholar
Li J, He Y, Hao J, Ni L, Dong C. High levels of eomes promote exhaustion of anti-tumor CD8(+) T cells. Front Immunol. 2018;9:2981.
Google Scholar
Neubert EN, DeRogatis JM, Lewis SA, Viramontes KM, Ortega P, Henriquez ML, et al. HMGB2 regulates the differentiation and stemness of exhausted CD8(+) T cells during chronic viral infection and cancer. Nat Commun. 2023;14:5631.
Google Scholar
Martinez GJ, Pereira RM, Aijo T, Kim EY, Marangoni F, Pipkin ME, et al. The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells. Immunity. 2015;42:265–78.
Google Scholar
Joulia E, Michieletto MF, Agesta A, Peillex C, Girault V, Le Dorze AL, et al. Eomes-dependent mitochondrial regulation promotes survival of pathogenic CD4+ T cells during inflammation. J Exp Med. 2024;221:e20230449.
Google Scholar
Banerjee A, Gordon SM, Intlekofer AM, Paley MA, Mooney EC, Lindsten T, et al. Cutting edge: the transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche. J Immunol. 2010;185:4988–92.
Google Scholar
Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, et al. Control of effector CD8+ T-cell function by the transcription factor Eomesodermin. Science. 2003;302:1041–3.
Google Scholar
Zeng L, Palaia I, Saric A, Su X. PLCγ1 promotes phase separation of T-cell signaling components. J Cell Biol. 2021;220:e202009154.
Google Scholar
Sullivan SA, Zhu M, Bao S, Lewis CA, Ou-Yang CW, Zhang W. The role of LAT-PLCgamma1 interaction in gammadelta T-cell development and homeostasis. J Immunol. 2014;192:2865–74.
Google Scholar
Cipriani B, Knowles H, Chen L, Battistini L, Brosnan CF. Involvement of classical and novel protein kinase C isoforms in the response of human V gamma 9 V delta 2 T cells to phosphate antigens. J Immunol. 2002;169:5761–70.
Google Scholar
Chan JD, Beavis PA, Darcy PK. p38 kinase: A key target for driving potent T cells for adoptive immunotherapy. Cancer Cell. 2020;37:756–8.
Google Scholar
Li X, Rong Y, Zhang M, Wang XL, LeMaire SA, Coselli JS, et al. Upregulation of thioredoxin interacting protein (TXNIP) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells. Biochem Biophys Res Commun. 2009;381:660–5.
Google Scholar
Nedellec S, Sabourin C, Bonneville M, Scotet E. NKG2D costimulates human V gamma 9 V delta 2 T-cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals. J Immunol. 2010;185:55–63.
Google Scholar
Muro R, Takayanagi H, Nitta. T. T-cell receptor signaling for gammadeltaT cell development. Inflamm Regen. 2019;39:6.
Google Scholar
Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:380–90.
Google Scholar
Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011;71:4562–72.
Google Scholar
Landin AM, Cox C, Yu B, Bejanyan N, Davila M, Kelley L. Expansion and enrichment of gamma-delta (γδ) T cells from apheresed human product. J Vis Exp. 2021;175:e62622.
Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther. 2014;25:1003.
Google Scholar
Park TS, Abate-Daga D, Zhang L, Zheng Z, Morgan RA. Gamma-retroviral vector design for the coexpression of artificial microRNAs and therapeutic proteins. Nucleic Acid Ther. 2014;24:356–63.
Google Scholar
Ramello MC, Benzaid I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, et al. An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci Signal. 2019;12:eaap9777.
Google Scholar
Welsh EA, Eschrich SA, Berglund AE, Fenstermacher DA. Iterative rank-order normalization of gene expression microarray data. BMC Bioinform. 2013;14:153.
Google Scholar
Amend SR, Valkenburg KC, Pienta KJ. Murine hind limb long bone dissection and bone marrow isolation. J Vis Exp. 2016;2016:53936.
